Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2

April W. Armstrong,1 Kim A. Papp, Joe Zhu,2 Brandon Becker,3 Yichen Zhong, Jennifer L. Beaumont,4 Michael De Rosa,5 Renata M. Kisa,1 Subhasis Banerjee,1 Bruce Strober4

1University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; 2University of Minnesota, Minneapolis, Minnesota, USA; 3University of California, San Francisco, San Francisco, California, USA; 4Fuchsia Research Solutions, Chicago, IL, USA; 5University of New Hamphire, USA; 6Provida Clinical Research, Emmen, The Netherlands; 7Corrona, Chicago, IL, USA; 8Amgen, Thousand Oaks, CA, USA

Received for peer review on October 15, 2019. Accepted for publication on December 10, 2019. This work may not be reproduced or distributed outside of the U.S. without permission from the American Academy of Dermatology. DOI: 10.1002/ad.21809

Conclusions
- Patients who experienced symptom reduction and improved patient quality of life were correlated with POETYK PSO-1 and POETYK PSO-2.

Acknowledgments
The authors wish to acknowledge the contributions of the following investigators to this study: A. Childs, M.D., L. Grossman, M.D., C. Hamilton, M.D., T. Tien, M.D. The authors also wish to acknowledge the contributions of the following investigators to this study: J. Allen, M.D., L. Grossman, M.D., C. Hamilton, M.D., T. Tien, M.D.

Disclosures
This study was sponsored by Bristol Myers Squibb. The corresponding author, J.Z., has received research grants and honoraria for the presentation of a poster or oral communication from Bristol Myers Squibb, Corrona, MedImmune, and Novartis. The other authors have declared no potential conflicts of interest. This study was sponsored by Bristol Myers Squibb. The corresponding author, J.Z., has received research grants and honoraria for the presentation of a poster or oral communication from Bristol Myers Squibb, Corrona, MedImmune, and Novartis. The other authors have declared no potential conflicts of interest.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2

April W. Armstrong,1 Kim A. Papp,1 Joe Zhuo,1 Brandon Becker,1 Yichen Zhong,1 Jennifer L. Beaumont,2 Michael DeRosa,2 Renata M. Kisa,1 Subhashis Banerjee,3 Bruce Strober3,4
1. New York School of Medicine, University of Southern California, Los Angeles, CA; 2. Moderna Medical Research, Merrimack, NH; 3. Eli Lilly and Company, Indianapolis, IN; 4. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 5. Weill Cornell Medicine, New York, NY; 6. Central Connecticut Dermatology, Cromwell, CT

Synopsis

Results are reported for patients receiving deucravacitinib or placebo who did and who did not achieve PASI 75 and sPGA 0/1 responses at Week 16. Change from baseline in relative PASI score was correlated with changes in the PSSD total score (Symptoms and Signs Diary (PSSD) total scores) and sPGA on one hand, and the PRO measures PSSD (Symptoms and Signs Diary [PSSD] total scores) and DLQI in the total study population.

At Week 16, 27.9% and 29.8% of all patients across both trials who did not achieve PASI 75 (188/674) vs 553/664 (83.3%) of all patients who achieved PASI 75 and 80.1% of deucravacitinib-treated patients who did not achieve PASI 75 (10.4% of patients who did not achieve PASI 75 and 10.3% who did not achieve sPGA 0/1) compared with patients who received placebo (72.7% of patients who achieved PASI 75 and 70.6% of patients who achieved sPGA 0/1) compared with patients who received placebo (72.7% of patients who achieved PASI 75 and 70.6% of patients who achieved sPGA 0/1).

| PSSD Domain | Pain | Tightness | Stinging | Itch |
|-------------|------|-----------|----------|------|
| 1 point     | 46.9 | 63.6      | 63.2     | 64.8 |
| 2 points    | 48.1 | 48.1      | 48.1     | 48.1 |
| 3 points    | 48.1 | 48.1      | 48.1     | 48.1 |
| 4 points    | 48.1 | 48.1      | 48.1     | 48.1 |

Total denominator includes patients who received apremilast.

Figure 2. DLQI change from baseline by PASI response group (treatment arms).

Figure 4. DLQI change from baseline by sPGA change group (treatment arms)
In the phase 3 clinical trials POETYK PSO-1 and PSO-2, deucravacitinib was compared for efficacy and safety with placebo and apremilast in the treatment of patients with moderate to severe plaque psoriasis.

— Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved by the US Food and Drug Administration for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

— In each clinical trial, greater proportions of patients who received deucravacitinib achieved ≥75% reduction from baseline in the Psoriasis Area and Severity Index score (PASI 75) and static Physician’s Global Assessment scores of 0 or 1 (sPGA 0/1), and showed meaningful improvements on Psoriasis Symptoms and Signs Diary (PSSD) total scores (≥25 points) and Dermatology Life Quality Index (DLQI) total scores (≥4 points) compared with patients receiving placebo or apremilast.

In this post hoc analysis of data pooled from both trials, clinical and patient-reported outcomes (PROs) were found to be correlated.

When analyzed by the deucravacitinib or placebo treatment arm, greater proportions of patients who received deucravacitinib reported symptom reduction and improved quality of life, both in patients who did and who did not achieve PASI 75 and sPGA 0/1 responses.

**Objective**

To explore the correlations between responses on clinical and PRO measures in pooled data from POETYK PSO-1 and PSO-2.

**Methods**

- In POETYK PSO-1 (N = 666) and PSO-2 (N = 1020) adults (aged ≥18 years) with moderate to severe psoriasis were randomized 2:1:1 to deucravacitinib 6 mg once daily, placebo, or apremilast 30 mg twice daily.
  - At Week 16 in each trial, patients who received placebo crossed over to deucravacitinib.

- Using data pooled from both trials, we evaluated the correlation between responses measured by PASI and sPGA on one hand, and the PRO measures PSSD (≥25 points) and DLQI (≥4 points) on the other.

  - The analysis populations for the PSSD and DLQI included all patients from the full analysis set who completed ≥1 item on the respective questionnaire at baseline and ≥1 post-baseline visit.
  - At baseline, 1659 patients had a DLQI score recorded and 1553 had a PSSD score recorded.

  - Spearman correlation coefficients between clinical and PRO score changes from baseline to Week 16 were calculated with all treatment groups combined.

  - Mean PSSD and DLQI scores were determined within relative PASI and sPGA response levels.

  - The proportions of patients achieving meaningful improvement (ie, response) in PSSD total scores and on the DLQI were summarized by whether they did or did not achieve PASI 75 and sPGA 0/1, and were further analyzed by treatment arm.

    - Results are reported for patients receiving deucravacitinib or placebo.

**Outcome measures**

- **PASI**
  - Clinician evaluated
  - Range: 0–72, with higher scores indicating more severe disease.

- **sPGA**
  - Clinician evaluated
  - Range: 0 (clear) to 4 (severe)

- **PSSD**
  - Patient rated
  - 5 skin symptoms (itch, tightness, burning, stinging, and pain) and 6 skin signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding) associated with psoriasis were rated 0 (absent) to 10 (worst imaginable); averages within each domain were multiplied by 10, then averaged across both domains to obtain a total score.
  - Range: 0–100, with higher scores indicating heavier disease burden.

- **DLQI**
  - Patient rated
  - 10 questions that assess the extent to which skin disease affects patients’ lives.
  - Range: 0–30, with higher scores indicating more severe impact of disease.

**Results**

**Correlations between clinical and PRO measures**

- At Week 16, change from baseline in relative PASI score was correlated with changes in the PSSD total score (Spearman’s rank correlation coefficient $r_s = 0.336$) and DLQI total score ($r_s = 0.421$) in the total study population.
Correlations between clinical and PRO measures

**Objective**

• Synopsis

In this post hoc analysis of data pooled from both trials, clinical and patient-reported outcomes (PROs) were measured, including PASI, sPGA, and PSSD total scores. The PRO measures, PSSD (Psoriasis Symptoms and Signs Diary), were calculated with all treatment groups combined.

When analyzed by the deucravacitinib or placebo treatment arm, greater proportions of patients who received deucravacitinib reported symptom reduction and improved quality of life, both in patients who did and who did not achieve PASI 75 and sPGA 0/1 responses.

Among patients with and without clinical response, greater proportions of patients treated with deucravacitinib were found to be correlated in one hand, and showed meaningful improvements on Psoriasis Area and Severity Index (PASI) and static Physician's Global Assessment (sPGA) responses at Weeks 16, 24, and 52 in the total study population (Figures 1-4).

| Symptom      | Deucravacitinib | Placebo | Apremilast |
|--------------|-----------------|---------|------------|
| Itch         | 58.7            | 58.4    | 58.7       |
| Tightness    | 58.4            | 58.8    | 58.4       |
| Burning      | 43.8            | 48.1    | 46.9       |
| Stinging     | 58.7            | 58.4    | 58.7       |
| Pain         | 58.7            | 58.4    | 58.7       |
| Dryness      | 58.7            | 58.4    | 58.7       |
| Cracking     | 58.7            | 58.4    | 58.7       |
| Redness      | 58.7            | 58.4    | 58.7       |

At baseline, the mean PSSD total score (SD) was 54.4 (23.3) in the deucravacitinib arm, 53.1 (23.9) in the placebo arm, and 55.7 (22.9) in the apremilast arm. PASI 50–100, 50%–100% improvement from baseline in the Psoriasis Area and Severity Index score; PSSD, Psoriasis Symptoms and Signs Diary.

**Figure 1. PSSD total score change from baseline by PASI response group (treatment arms and trials pooled, n = 1536)**

**Figure 2. DLQI Change from baseline by PASI response group (treatment arms and trials pooled, n = 1643)**

**Figure 3. PSSD change from baseline by sPGA* change group (treatment arms and trials pooled, n = 1536)**

---

*PSSD, Psoriasis Symptoms and Signs Diary; sPGA, static Physician’s Global Assessment.

---

Table 1. PSSD response at Week 16 in patients who achieved clinical response

| PASI 75 | PASI 50–74 | PASI 75–89 | PASI 90–99 | PASI 100 |
|---------|------------|------------|------------|----------|
| 323/549 (58.8) | 284/385 (73.8) | 10/32 (31.3) | 10/32 (31.3) | 10/32 (31.3) |

Table 2. DLQI response at Week 16 in patients who achieved clinical response

| PASI 75 | PASI 50–74 | PASI 75–89 | PASI 90–99 | PASI 100 |
|---------|------------|------------|------------|----------|
| 359/431 (83.3) | 23/36 (63.9) | 10/32 (31.3) | 10/32 (31.3) | 10/32 (31.3) |

---

1. Warren RB, et al. 2. Papp KA, et al. [poster] Presented at the 30th Congress of the European Academy of Dermatology and Venereology (EADV); September 29.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical response.

Objective
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical response.

Outcome measures
1. Psoriasis Area and Severity Index (PASI)
2. Static Physician's Global Assessment (sPGA)
3. Dermatology Life Quality Index (DLQI)
4. Psoriasis Symptoms and Signs Diary (PSSD)

Results

PSSD Response by Clinical Response

- At Week 16, PSSD total score response (≥25-point reduction from baseline) was reported by 64.8% and 65.3% of all patients across both trials who achieved PASI 75 (356/549) and/or sPGA 0/1 (330/505), respectively (Table 1).
  - Greater proportions of patients who received deucravacitinib and achieved clinical response reported PSSD total score response (68.6% of patients who achieved PASI 75 and 68.7% of patients who achieved sPGA 0/1) compared with patients who received placebo (31.3% of patients who achieved PASI 75 and 37.0% of patients who achieved sPGA 0/1) (Table 1).
  - On the PSSD itch item, meaningful improvement (≥2 points) was reported by 80.8% of patients receiving deucravacitinib who achieved PASI 75 and 80.1% of deucravacitinib-treated patients who achieved sPGA 0/1, compared with 43.8% of patients receiving placebo who achieved PASI 75 and 48.1% of placebo-treated patients who achieved sPGA 0/1 (Figure 5).

- At Week 16, 27.9% and 29.8% of all patients across both trials who did not achieve PASI 75 (188/674) and/or did not achieve sPGA 0/1 (214/718), respectively, nonetheless reported PSSD total score response.
  - Greater proportions of patients who received deucravacitinib and did not achieve clinical response nonetheless reported PSSD total score response (41.8% of patients who did not achieve PASI 75 and 44.1% of patients who did not achieve sPGA 0/1) compared with patients who received placebo (10.4% of patients who did not achieve PASI 75 and 10.3% who did not achieve sPGA 0/1).
  - On the PSSD itch item, meaningful improvement was reported by 54.9% of patients receiving deucravacitinib who did not achieve PASI 75 compared with 22.0% of patients receiving placebo who did not achieve PASI 75.

Table 1. PSSD response at Week 16 in patients who achieved clinical response

| PSSD Domain | Total patients | Deucravacitin n = 765 | Placebo n = 383 |
|-------------|----------------|------------------------|-----------------|
| Total score (≥25-point reduction), n/N (%) | PASI 75 sPGA 0/1 | 356/549 (64.8)% | 264/385 (68.6) | 10/12 (31.3) |
| Symptom score (≥25-point reduction), n/N (%) | PASI 75 sPGA 0/1 | 323/549 (58.8)% | 240/385 (62.3) | 8/27 (29.6) |
| Sign score (≥25-point reduction), n/N (%) | PASI 75 sPGA 0/1 | 383/549 (69.8)% | 284/385 (73.8) | 10/12 (31.3) |

Table 2. DLQI response at Week 16 in patients who achieved clinical response

**Figure 5. PSSD individual item response at Week 16 in patients who achieved clinical response**

- Total denominator includes patients who achieved clinical response and were completable for their primary outcome data at baseline or week 16.
- Total denominator includes patients who received apremilast.

**AWA:** Medical writing and editorial assistance was provided by Eleanor Bush, MA, of Peloton Advantage, LLC, an OPEN Health company, and funded by Bristol Myers Squibb.
• At Week 16, DLQI response (≥25-point reduction from baseline) was reported by 83.3% and 82.5% of all patients across both trials who achieved PASI 75 (553/664) and/or sPGA 0/1 (496/601), respectively (Table 2)
  — Greater proportions of patients who received deucravacitinib and achieved clinical response reported meaningful DLQI improvement (84.7% of patients who achieved PASI 75 and 83.3% of patients who achieved sPGA 0/1) compared with patients who received placebo (72.7% of patients who achieved PASI 75 and 70.6% of patients who achieved sPGA 0/1)

• At Week 16, 54.7% and 57.3% of all patients across both trials who did not achieve PASI 75 (444/811) and/or did not achieve sPGA 0/1 (501/874), respectively, nonetheless reported DLQI response
  — Greater proportions of patients who received deucravacitinib and did not achieve clinical response nonetheless reported meaningful DLQI improvement (67.1% of patients who did not achieve PASI 75 and 70.8% of patients who did not achieve sPGA 0/1) compared with patients who received placebo (40.5% of patients who did not achieve PASI 75 and 41.7% who did not achieve sPGA 0/1)

**Table 2. DLQI response at Week 16 in patients who achieved clinical response**

| DLQI ≥25-point reduction | Total patients N = 1643 | Deucravacitinib n = 824 | Placebo n = 659 |
|--------------------------|-------------------------|-------------------------|----------------|
| PASI 75, n/N (%)         | 553/664 (83.3)%         | 393/464 (84.7)          | 32/44 (72.7)  |
| sPGA 0/1, n/N (%)        | 496/601 (82.5)%         | 359/431 (83.3)          | 24/34 (70.6)  |

1. The denominator includes the patients who achieved clinical response and completed ≥1 DLQI from baseline and ≥1 DLQI time at post-baseline visit.
2. The denominator includes patients who received at least 1 dose of study drug.

**Conclusions**

- Psoriasis skin clearance, symptom reduction, and improved patient quality of life were correlated in the POETYK PSO-1 and PSO-2 trials
- This correlation is consistent with that determined in other studies
- Higher clinical response was associated with greater PRO measure response
- PRO measures capture patient-perceived treatment benefits that may not be ascertained by measuring rates of skin clearance with clinical assessments alone
- Psoriasis bears symptoms, such as pruritus, for which there are no validated objective measures, or which are best assessed by patients themselves in order to evaluate treatment efficacy
- Among patients who achieved PASI 75 at Week 16, 80.8% of patients who received deucravacitinib reported meaningful itch improvement on the PSSD compared with 43.8% of patients who received placebo
- Among patients with and without clinical response, greater proportions of patients treated with deucravacitinib reported improved itch in their self-reported symptom signs, and quality of life compared with patients treated with placebo

**References**

1. Warren RB, et al. Am J Rheum Dis. 2022;81:1570-1571.
2. Papp KA, et al. [Poster] Presented at the 50th Congress of the European Academy of Dermatology and Venereology (EADV); September 29-October 2, 2021; virtual meeting.
3. Augustin N, et al. [Poster] Presented at the American Academy of Dermatology (AAD) Annual Meeting; March 25-29, 2022; Boston, MA.
4. Armstrong MK, et al. J Clin Dermatol. 2019;20:155-164.
5. Luft MD, et al. Acta Derm Venereol. 2019;99:1224-1230.
6. Schäfer I, et al. Eur J Dermatol. 2010;20:62-67.
7. Thaci D, et al. Dermatol Ther (Heidelb). 2022;12:495-510.
8. Price A, Cohen DE. Dermatitis. 2014;25:334-344.
9. Armstrong MK, et al. J Dermatol Treat. 2019;30:27-34.

**Acknowledgments**

- This study was sponsored by Bristol-Myers Squibb
- Medical writing and editorial assistance was provided by Elsevier Bush, Inc., of Peloton Advantage, LLC, an OPEN Health company, and funded by Bristol-Myers Squibb

**Disclosures**

- **AMH:** Grants and personal fees: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Leo Pharma, and Novartis; Personal fees: Boehringer Ingelheim/Parexel, Celgene, Dermvertex, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, and Valeant; Grant/research support: AbbVie, Amgen, Asana, Artex, Astellas, AstraZeneca, Basilea, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Dermvertex, Gilead, GlaxoSmithKline, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck Sharp & Dohme, Novartis, Pfizer, and Valeant; Employees and shareholders of Bristol-Myers Squibb
- **BB, YZ, RWH, and SB:** Employees and shareholders of Bristol-Myers Squibb
- **JB and MD:** Employees of Clinical Outcomes Solutions, which has received consulting fees from Bristol-Myers Squibb
- **Bl:** Consultant (Honoraria): AbbVie, Almirall, Amgen, Arieus, Astra, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Connect Biopharma, Dermvertex, Eli Lilly, Equilibra, Gilead/Genentech, Immune Therapeutics, Janssen, Leo Pharma, Merck Sharp & Dohme, Merck Serono, Novartis, Ortho Dermatologica, Pfizer, Regeneron, Sanofi Genzyme, Sanofi, Sun Pharma, UCB, Vertex Biologics, and V7 Therapeutics; Speaker: AbbVie, Eli Lilly, Janssen, and Sanofi Genzyme; Co-scientific director (consulting fees): CoreVax (Carrus) Psoriasis Registry; Investigator: AbbVie, Car, CoreVax (Carrus) Psoriasis Registry, Dermvertex, Derma, and Novartis
Results are reported for patients receiving deucravacitinib or placebo on the DLQI were summarized by whether they did or did not achieve PASI 75 and sPGA 0/1, and were mean PSSD and DLQI scores were determined within relative PASI and sPGA response levels when analyzed by the deucravacitinib or placebo treatment arm, greater proportions of patients who received deucravacitinib and achieved clinical response reported meaningful DLQI improvement (84.7% of patients who achieved PASI 75 and 83.3% of patients who did not achieve PASI 75 and 41.7% who did not achieve sPGA 0/1) compared with patients who received placebo (72.7% of patients who achieved sPGA 0/1) compared with patients who received placebo (31.3% of patients who achieved PASI 75 and 44.1% of patients who did not achieve sPGA 0/1) compared with patients who received placebo (22.0% of patients receiving placebo who did not achieve PASI 75 compared with 22.0% of patients receiving placebo who did not achieve PASI 75).